Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

BURJC-Digital. Repositorio Institucional de la Universidad Rey Juan Carlos
Publication Artículo científico (JournalArticle)

Profiling of Human Circulating Dendritic Cells and Monocyte Subsets Discriminates Between Type and Mucosal Status in Patients With Inflammatory Bowel Disease

  • Ortega Moreno, Lorena
  • Fernández-Tomé, Samuel
  • Chaparro, María
  • Marin, Alicia C
  • Mora-Gutierrez, Irene
  • Santander, Cecilio
  • Baldan-Martin, Montse
  • Gisbert, Javier P.
  • Bernardo, David
[Background]: Intestinal dendritic cells (DC) and macrophages drive disease progression in patients with inflammatory bowel disease (IBD). We aimed to characterize the activation and homing profile of human circulating DC and monocyte subsets in healthy control patients (CP) and IBD patients., This work was supported by the Spanish Ministry of Science (SAF2014-56642-JIN; RYC-2017–21606), the Instituto de Salud Carlos III (PIE13/00041), the Sara Borrell fellowship CD17/00014), the Asociación Española de Gastroenterología (Becas Nuevos Investigadores 2016), and the Community of Madrid (Consejería de Educación, Juventud y Deporte, Programa de Garantía Juvenil 2015 and 2016; Universidad Autónoma de Madrid, Ayudas Atracción de Talento modalidad 2 2017 [BMD-5800]).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Immunogenetic pathogenesis of celiac disease and non-celiac gluten sensitivity

  • Escudero-Hernández, Celia
  • Salvador Peña, Amado
  • Bernardo, David
Celiac disease is the most common oral intolerance in Western countries. It results from an immune response towards gluten proteins from certain cereals in genetically predisposed individuals (HLA-DQ2 and/or HLA-DQ8). Its pathogenesis involves the adaptive (HLA molecules, transglutaminase 2, dendritic cells, and CD4 T-cells) and the innate immunity with an IL-15-mediated response elicited in the intraepithelial compartment. At present, the only treatment is a permanent strict gluten-free diet (GFD). Multidisciplinary studies have provided a deeper insight of the genetic and immunological factors and their interaction with the microbiota in the pathogenesis of the disease. Similarly, a better understanding of the composition of the toxic gluten peptides has improved the ways to detect them in food and drinks and how to monitor GFD compliance via non-invasive approaches. This review, therefore, addresses the major findings obtained in the last few years including the re-discovery of non-celiac gluten sensitivity., DB is funded by the Spanish Ministry of Economy (Proyectos de I+D+I para jóvenes investigadores SAF2014-56642-JIN)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Peptides encrypted in the human intestinal microbial-exoproteome as novel biomarkers and immunomodulatory compounds in the gastrointestinal tract

  • Fernández-Tomé, Samuel
  • Montalban-Arques, Ana
  • Díaz-Guerra, Alba
  • Galvan-Roman, José M.
  • Marin, Alicia C.
  • Mora-Gutiérrez, Irene
  • Ortega Moreno, Lorena
  • Santander, Cecilio
  • Sánchez García, Borja
  • Chaparro, María
  • Gisbert, Javier P.
  • Bernardo, David
Peptides encrypted in the intestinal microbial-exoproteome mediate the host-microbiota crosstalk, which is disrupted in inflammatory bowel disease (IBD). Here, the MAHMI database was used for the identification of 20 novel intestinal bacterial peptides. Our results revealed that serum IgA levels directed towards the peptides, but not IgG, discriminated healthy controls from IBD patients. Indeed, they also differentiated patients with ulcerative colitis from Crohńs disease and, within them, patients with and without intestinal inflammation. All peptides were immunomodulatory as they changed the intestinal cytokine milieu following human lamina propria mononuclear cells culture (with/out LPS), revealing a Bifidobacterium longum subsp. longum peptide with the highest tolerogenic properties. Therefore, bacterial peptides encrypted in the human gut metaproteome may have utility as non-invasive biomarkers to aid on IBD diagnosis and monitoring. These peptides also display immunomodulatory effects on the intestinal mucosa revealing them as novel functional compounds for non-drug therapeutic strategies in IBD., This research was funded by the Spanish Ministry of Economy (SAF2014-56642-JIN), the Spanish Ministry of Health (PIE13/00041), ACAD (Asociación Castellana de Aparato Digestivo), GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa) and the Community of Madrid (Consejería de Educación, Juventud y Deporte, Programa de Garantía Juvenil 2015 y 2016). SFT acknowledges the “Instituto de Salud Carlos III” for his “Sara Borrell” fellowship (CD17/00014). BS acknowledges the support of the “Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad” (AGL2013-44039R) for implementing the MAHMI database., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Utilidad como biomarcador de los niveles circulantes de IgG e IgA frente al péptido STp derivado de Lactobacillus plantarum en pacientes con enfermedad inflamatoria intestinal

  • Sánchez García, Borja
  • Margolles Barros, Abelardo
Trabajo presentado en la XIX Reunión Anual de la Asociación Española de Gastroenterología (AEG), celebrado en Madrid (España) del 1 al 4 de marzo de 2016, Este proyecto ha sido financiado por el Ministerio de Economía y Competitividad (Proyectos de I+D+I para jóvenes investigadores SAF2014-56642-JIN, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Immunomodulatory effect of gut microbiota-derived bioactive peptides on human immune system from healthy controls and patients with inflammatory bowel disease

  • Fernández-Tomé, Samuel
  • Marin, Alicia C.
  • Ortega Moreno, Lorena
  • Baldan-Martin, Montserrat
  • Mora-Gutiérrez, Irene
  • Lanas-Gimeno, Aitor
  • Moreno-Monteagudo, J. A.
  • Santander, Cecilio
  • Sánchez García, Borja
  • Chaparro, María
  • Gisbert, Javier P.
  • Bernardo, David
Bioactive peptides secreted by probiotic Bifidobacterium longum (peptide B7) and opportunistic pathogen Bacteroides fragilis (peptide B12) modulate the intestinal cytokine milieu in health. Here, we characterized their capacity to modulate both the mucosal cytokine production and the phenotype of circulating antigen presenting cells (APCs) in active inflammatory bowel disease (IBD). The IBD mucosa produced higher levels of pro-inflammatory cytokines referred to healthy controls (HCs). Peptides B7 and B12, however, did not ameliorate the mucosal cytokine milieu in IBD. Human circulating APCs (B-cells, monocytes, plasmacytoid dendritic cells (pDCs), and conventional dendritic cells (cDCs)) were characterized by flow cytometry in presence/absence of the peptides. Circulating B-cells, monocytes, and cDCs from IBD patients were more activated than those from HCs. Peptide B7, but not B12, decreased CCR2 expression on all APC subsets from HC, but not IBD patients. Moreover, both peptides tend to further increase their pro-inflammatory profile in IBD. In summary, IBD patients display mucosal and circulating APC pro-inflammatory properties. Peptide B7 immunomodulatory capacity elicited over circulating APCs from HC, but not IBD patients, suggests the presence of disrupted modulatory mechanisms for this peptide in IBD. Future studies should address the effect of bacteria-derived immunomodulatory peptides in non-inflamed (quiescent) IBD patients., S.F.T. is currently funded by the Instituto de Salud Carlos III (Sara Borrell fellowship CD17/00014). L.O.M. is funded by the Community of Madrid (BMD-5800). D.B. is funded by the Spanish Ministry of Science (RYC-2017-21606). This work was supported by the Spanish Ministry of Economy (SAF2014-56642-JIN), the Spanish Ministry of Health (PIE13/00041), GETECCU (Grupo Español de Trabajo en Enfermedad Crohn y Colitis Ulcerosa), and the Community of Madrid (Consejería de Educación, Juventud y Deporte, Programa de Garantía Juvenil 2015 and 2016)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A quick flow cytometry protocol to assess Helicobacter pylori viability

  • Alba, Claudio
  • Marin, Alicia C.
  • McNicholl, Adrian G.
  • Montalban-Arques, Ana
  • Mora-Gutiérrez, Irene
  • Sánchez-Arroyo, Antonio José
  • Soler, Tamara
  • García-Fresnadillo, David
  • Gisbert, Javier P.
  • Alarcón, Teresa
  • Bernardo, David
Here we present an easy flow cytometry protocol to study the viability of Helicobacter pylori which also enables the detection of even low live bacteria densities. This protocol has potential utility for a fast and accurate assessment of experimental eradication methods against H. pylori., This work was supported by the Spanish Ministry of Reseach (RyC-2017-21606), Consejería de Educación, Juventud y Deporte de Madrid (Programa de Garantía Juvenil 2015-2016), and Ministerio de Economía y Competitividad (MINECO; projects CTQ2017-84327-P, CTQ2017-83531-R, CTQ2015-71896-REDT, SAF2014-56642-JIN).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lunasin Peptide is a Modulator of the Immune Response in the Human Gastrointestinal Tract

  • Fernández-Tomé, Samuel
  • Indiano-Romacho, Pedro
  • Mora-Gutiérrez, Irene
  • Pérez-Rodríguez, Leticia
  • Ortega Moreno, Lorena
  • Marin, Alicia C.
  • Baldan-Martin, Montserrat
  • Moreno-Monteagudo, J. A.
  • Santander, Cecilio
  • Chaparro, María
  • Hernández-Ledesma, Blanca
  • Gisbert, Javier P.
  • Bernardo, David
[Introduction]: Lunasin is a soybean bioactive peptide with a variety of beneficial properties against chronic disorders. However, its effect in human primary intestinal cells remains unknown. Hence, this study aims to characterize its ex vivo biological activity in the human intestinal mucosa. [Methods and Results]: Human intestinal biopsies, obtained from healthy controls, are ex vivo conditioned with lunasin both in the presence/absence of lipopolysaccharide (LPS). Peptide maintains its stability during biopsy culture by HPLC-MS/MS analysis. Lunasin is bioactive in the human mucosa, as it induces IL-1β, TNF-α, IL-17A, CCL2, and PGE2/COX-2 gene expression together with an increased expression of tolerogenic IL-10 and TGFβ, while it also downregulates the expression of iNOS and subunit p65 from NF-κB. Indeed, lunasin also abrogates the LPS-induced pro-inflammatory response, downregulating IL-17A, IFNγ, and IL-8 expression, and inducing IL-10 and TGFβ expression. These results are also mirrored in the cell-free culture supernatants at the protein level by Multiplex. Moreover, lunasin further induces a regulatory phenotype and function on human intestinal conventional dendritic cell and macrophage subsets as assessed by flow cytometry. [Conclusions]: We hereby have characterized lunasin as an immunomodulatory peptide with potential capacity to prevent immune and inflammatory-mediated disorders in the human gastrointestinal tract., This work was supported by the Spanish Ministry of Economy (SAF2014-56642-JIN), the Spanish Ministry of Health (PIE13/00041), the Spanish Ministry of Science, Innovation and Universities (AGL2015-66886-R, PID2019-104218RB-I00), and the Community of Madrid (Consejería de Educación, Juventud y Deporte, Programa de Garantía Juvenil 2015 and 2016). S.F.T. is currently funded by the Instituto de Salud Carlos III (Sara Borrell fellowship CD17/00014). L.O.M. is funded by the Community of Madrid (BMD-5800). D.B. is funded by the Spanish Ministry of Science (RYC-2017-21606).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Profiling of Human Circulating Dendritic Cells and Monocyte Subsets Discriminates between Type and Mucosal Status in Patients with Inflammatory Bowel Disease

  • Ortega Moreno, Lorena
  • Fernández-Tomé, Samuel
  • Chaparro, María
  • Marin, Alicia C.
  • Mora-Gutiérrez, Irene
  • Santander, Cecilio
  • Baldan-Martin, Montserrat
  • Gisbert, Javier P.
  • Bernardo, David
[Background]: Intestinal dendritic cells (DC) and macrophages drive disease progression in patients with inflammatory bowel disease (IBD). We aimed to characterize the activation and homing profile of human circulating DC and monocyte subsets in healthy control patients (CP) and IBD patients., [Methods]: Eighteen CP and 64 patients with IBD were categorized by diagnoses of Crohn disease (CD) and ulcerative colitis (UC), either endoscopically active (inflamed) or quiescent. Circulating type 1 conventional DC, type 2 conventional DC, plasmacytoid DC, classical monocytes, nonclassical monocytes, and intermediate monocytes were identified by flow cytometry in each individual and characterized for the expression of 18 markers. Association between DC/monocytes and IBD risk was tested by logistic regression. Discriminant canonical analyses were performed to classify the patients in their own endoscopy category considering all markers on each subset., [Results]: CCRL1, CCR3, and CCR5 expression on circulating type 1 DC; CCRL1 expression on nonclassical monocytes; and CCR9 and β7 expression on classical monocytes allowed us to discriminate among the different study groups. Indeed, the same markers (excluding β7) were also associated with IBD when all DC and monocyte subsets were considered at the same time., [Conclusions]: Monitoring the phenotype of human circulating DC and monocyte subsets may provide novel tools as biomarkers for disease diagnosis (CD/UC) or mucosal status (inflamed/noninflamed) in the absence of an invasive colonoscopy., This work was supported by the Spanish Ministry of Science (SAF2014-56642-JIN; RYC-2017–21606), the Instituto de Salud Carlos III (PIE13/00041), the Sara Borrell fellowship CD17/00014), the Asociación Española de Gastroenterología (Becas Nuevos Investigadores 2016), and the Community of Madrid (Consejería de Educación, Juventud y Deporte, Programa de Garantía Juvenil 2015 and 2016; Universidad Autónoma de Madrid, Ayudas Atracción de Talento modalidad 2 2017 [BMD-5800]).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

  • Chaparro, M.
  • Barreiro-de Acosta, M.
  • Echarri, A.
  • Almendros, R.
  • Barrio, J.
  • Llao, J.
  • Gomollón, F.
  • Vera, M.
  • Cabriada, J.L.
  • Guardiola, J.
  • Guerra, I.
  • Beltrán, B.
  • Roncero, O.
  • Busquets, D.
  • Taxonera, C.
  • Calvet, X.
  • Ferreiro-Iglesias, R.
  • Ollero Pena, V.
  • Bernardo, D.
  • Donday, M.G.
  • Garre, A.
  • Godino, A.
  • Díaz, A.
  • Gisbert, J.P.
Objectives: (a) To evaluate the diagnostic accuracy of anti-TNF trough levels to predict mucosal healing in inflammatory bowel disease (IBD); (b) to determine the best cut-off point to predict mucosal healing in IBD patients treated with anti-TNF. Methods: This is a multicenter, prospective study. IBD patients under anti-TNF treatment for at least 6 months that had to undergo an endoscopy were included. Mucosal healing was defined as: Simple endoscopic score for Crohn’s Disease < 3 for Crohn’s disease (CD), Rutgeerts score < i2 for CD in postoperative setting, or Mayo endoscopic score = 1 for ulcerative colitis (UC). Anti-TNF concentrations were measured using SMART ELISAs at trough. Results: A total of 182 patients were included. Anti-TNF trough levels were significantly higher among patients that had mucosal healing than among those who did not. The area under the curve of infliximab for mucosal healing was 0.63 (best cutoff value 3.4 µg/mL), and for adalimumab 0.60 (best cutoff value 7.2 µg/mL). In the multivariate analysis, having anti-TNF drug levels above the cutoff values [odds ratio (OR) 3.1]) and having UC instead of CD (OR 4) were associated with a higher probability of having mucosal healing. Additionally, the need for an escalated dosage (OR 0.2) and current smoking habit (OR 0.2) were also associated with a lower probability of mucosal healing. Conclusions: There was an association between anti-TNF trough levels and mucosal healing in IBD patients; however, the accuracy of the determination of infliximab and adalimumab concentrations able to predict mucosal healing was suboptimal.